S. Eipeldauer

Bevacizumab protects against sinusoidal obstruction syndrome and does not increase response rate in neoadjuvant XELOX/FOLFOX therapy of colorectal cancer liver metastases.

T. Gruenberger, D. Tamandl, B. Gruenberger, 2009, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

Sinusoidal Obstruction Syndrome Impairs Long-Term Outcome of Colorectal Liver Metastases Treated with Resection after Neoadjuvant Chemotherapy

T. Gruenberger, D. Tamandl, K. Kaczirek, 2011, Annals of Surgical Oncology.

Bevacizumab Improves Pathological Response of Colorectal Cancer Liver Metastases Treated with XELOX/FOLFOX

Markus Klinger, Thomas Gruenberger, Stefan Hacker, 2010, Annals of Surgical Oncology.